Frank Vinluan is a senior biopharma reporter for MedCity News. He covers a range of topics within medicine and healthcare, including pharmaceuticals, medical technology, and healthcare technology, with a particular focus on oncology, immunology, and gene therapy. Frank's work has been featured in NewsBreak, MedCity News, RamaOnHealthcare, and Breaking Media, Inc.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Frank Vinluan's coverage is heavily focused on the healthcare and pharmaceutical industry, with an emphasis on mergers and acquisitions, drug development, FDA approvals, and biotech. He frequently cites data in his articles, indicating a reliance on factual evidence.
Given his focus on M&A deals and drug developments within the healthcare sector, Frank may be interested in receiving pitches related to exclusive insights from industry experts or company executives involved in these transactions or new developments. Pitches emphasizing unique data-driven analyses or perspectives from key opinion leaders could also resonate well with him.
As there is no specific geographic focus mentioned for Frank's reporting, relevant news or expert analysis from any location within the global pharmaceutical and biotech industries would likely be of interest to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Frank Vinluan
Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering the potential for better efficacy compared to other next-generation migraine drugs in R&D.
By: Frank Vinluan
Amylyx Pharmaceuticals’ avexitide led to statistically significant and clinically meaningful reductions in hypoglycemic events in patients with post-bariatric hypoglycemia (PBH). This peptide drug, a GLP-1 antagonist, was acquired from Eiger BioPharmaceuticals in 2024.
By: Frank Vinluan
Merck and Moderna said intismeran autogene, an mRNA cancer vaccine that prompts an immune response to proteins expressed by a patient's tumors, met the main goal of a pivotal test in melanoma. It's the most advanced trial in a 50/50 partnership evaluating the personalized cancer treatment in a wide range of tumor types.
By: Frank Vinluan
Ultragenyx Pharmaceutical's Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It's also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments.
By: Frank Vinluan
Along with Ambros Therapeutics’ merger with Werewolf Therapeutics, the combined company will raise $150 million in a private placement. Ambros is in Phase 3 testing with a drug developed for treating a type of pain that does not respond to currently available medicines, including opioids.
By: Frank Vinluan
Abcuro will apply the capital to a study that could support a biologics license application in inclusion body myositis, a rare inflammatory disorder that leads to worsening muscle weakness. A Phase 2/3 study failed earlier this year, but Abcuro saw positive trends in patients with less severe disease.
By: Frank Vinluan
Abcuro will apply the capital to a study that could support a biologics license application in inclusion body myositis, a rare inflammatory disorder that leads to worsening muscle weakness.
By: Frank Vinluan
Hanmi Pharmaceutical’s drug is designed to activate a receptor in skeletal muscle to both increase muscle mass and reduce fat. This engineered peptide gives Roche a clinical-stage asset that addresses a different target than the other obesity drugs in its pipeline.
By: Frank Vinluan
Johnson & Johnson antibody drug Imaavy expanded its label to include the treatment of warm autoimmune hemolytic anemia (wAIHA). Projected to become a blockbuster seller across multiple indications, Imaavy was first approved last year for treating generalized myasthenia gravis.
By: Frank Vinluan
FDA approval of Revolution Medicines' daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common type of pancreatic cancer. The speedy regulatory nod specifically covers advanced cases of this type of cancer, which has had limited treatment options.
